QCI Interpret for Oncology
Precision medicine for any cancer assay on any platform
914 views
For NGS cancer testing, keeping pace with new discoveries is a serious bottleneck. Valuable information can go undetected due to inadequate mining and interpretation mechanisms. These are called "knowledge blind spots" and can have significant clinical consequences.
QIAGEN is the world leader in aggregating genetic disease knowledge resources. For the past 20 years, we have partnered with clinical testing labs throughout the world to manually curate genetic evidence across all human genes (23,000).
N-of-One’s approach combines expert curation, the insights of oncology experts, and a proprietary technology and knowledgebase, MarkerMine™, to provide curated, high-quality, and actionable clinical interpretation of molecular tests.
Join us for an informative webinar about both clinical interpretation solutions.
Speakers: Dan Richards, Ph.D., Vice President of Biomedical Informatics at QIAGEN Sheryl Elkin, Ph.D., Chief Scientific Officer of N-of-One, Inc.Less
Interested in learning more?
Click here
Speakers: Dan Richards, Ph.D., Vice President of Biomedical Informatics at QIAGEN Sheryl Elkin, Ph.D., Chief Scientific Officer of N-of-One, Inc.Less
Related videos
QCI Interpret for Oncology
Rapid, evidence-based reporting of oncology NGS tests at scale
Competing to offer a comprehensive genomic profiling service for solid or...
QCI Interpret for Oncology
Gaining insights with transcriptomic profiling and mechanistic modeling
In this webinar, Moritz Schütte, head of next-generation sequencing data...
QCI Interpret for Oncology
Going beyond: Molecular evidence for off-label therapy use
Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN...
QCI Interpret for Oncology
Confidence and trust: Deliver valuable clinical insights with high-quality knowledge
Ben Turner, Director of Bioinformatics Enterprise Solutions, QIAGEN Digital...